Differential Diagnosis of Meningeal SFT-HPC and Meningioma Which ă Immunohistochemical Markers Should Be Used?

Nicolas Macagno (), Dominique Figarella-Branger (), Karima Mokthari, Philippe Metellus, Anne Jouvet (), Alexandre Vasiljevic, Anderson Loundou and Corinne Bouvier
Additional contact information
Dominique Figarella-Branger: CRO2 - Centre de Recherches en Oncologie biologique et Oncopharmacologie - AMU - Aix Marseille Université - TIMONE - Hôpital de la Timone [CHU - APHM] - INSERM - Institut National de la Santé et de la Recherche Médicale, TIMONE - Hôpital de la Timone [CHU - APHM]
Philippe Metellus: CRO2 - Centre de Recherches en Oncologie biologique et Oncopharmacologie - AMU - Aix Marseille Université - TIMONE - Hôpital de la Timone [CHU - APHM] - INSERM - Institut National de la Santé et de la Recherche Médicale
Anne Jouvet: Hôpital neurologique et neurochirurgical Pierre Wertheimer [CHU - HCL] - HCL - Hospices Civils de Lyon
Alexandre Vasiljevic: Service de Pathologie - HCL - Hospices Civils de Lyon - Hôpital neurologique et neurochirurgical Pierre Wertheimer [CHU - HCL] - HCL - Hospices Civils de Lyon
Anderson Loundou: Unité d'Aide Méthodologique - APHM - Assistance Publique - Hôpitaux de Marseille - CHU Marseille
Corinne Bouvier: ECOLAG - Ecosystèmes lagunaires : organisation biologique et fonctionnement - UM2 - Université Montpellier 2 - Sciences et Techniques - IFREMER - Institut Français de Recherche pour l'Exploitation de la Mer - CNRS - Centre National de la Recherche Scientifique

Post-Print from HAL

Abstract: Meningeal solitary fibrous tumors-hemangiopericytomas (SFT-HPC) and ă meningiomas can be difficult to distinguish on histologic examination. ă STAT6 immunohistochemistry (IHC) is a reliable diagnostic marker of ă SFT-HPCs. Recently, GRIA2 has also been reported to be a diagnostic ă marker of SFT-HPC, although no extensive data are available for ă meningeal SFT-HPCs yet. The aim of this study was to test their ă diagnostic performance in a large cohort of SFT-HPCs and meningiomas. ă IHC analyses for GRIA2 and STAT6 were performed on tissue microarrays ă containing 76 SFT-HPCs and 181 meningiomas. Results were compared with ă previous data with ALDH1 and CD34. Two different anti-STAT6 antibodies ă were tested: SC-20 polyclonal and YE361 monoclonal antibody. Ninety-six ă percent of meningeal SFT-HPCs but no meningioma displayed nuclear STAT6 ă positivity. With SC-20 antibody, concomitant cytoplasmic staining for ă STAT6 was observed in > 50% of all cases, including meningiomas. ă However, using YE361 antibody, cytoplasmic staining was absent, and ă nuclear signal intensity was stronger leading to better interpretation ă of STAT6 IHC. GRIA2 was positive in 84% of SFT-HPCs and in 16% of ă meningiomas. STAT6 had excellent sensitivity (96%) and specificity ă (100%), ALDH1 and GRIA2 had same sensitivity (84%), but ALDH1 and CD34 ă had better specificity than GRIA2 (97% and 96% vs. 84%, ă respectively). For the differential diagnosis of SFT-HPCs versus ă meningiomas, the best diagnostic approach is to perform STAT6, followed ă by ALDH1 and CD34 in the case of uncommon STAT6-negative cases. Because ă of meningioma positivity, GRIA2 seems less useful in this indication.

Keywords: Quality (search for similar items in EconPapers)
Date: 2016-02
References: Add references at CitEc
Citations:

Published in American Journal of Surgical Pathology, 2016, 40 (2), pp.270-278. ⟨10.1097/PAS.0000000000000526⟩

There are no downloads for this item, see the EconPapers FAQ for hints about obtaining it.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:hal:journl:hal-01482516

DOI: 10.1097/PAS.0000000000000526

Access Statistics for this paper

More papers in Post-Print from HAL
Bibliographic data for series maintained by CCSD ().